Literature DB >> 25363844

Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer.

C Alberti1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25363844      PMCID： PMC4277386          DOI： 10.1259/bjr.20140630

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


× No keyword cloud information.
  6 in total

1.  CXCR4 as biomarker for radioresistant cancer stem cells.

Authors:  Franziska Trautmann; Monica Cojoc; Ina Kurth; Nicolas Melin; Laure C Bouchez; Anna Dubrovska; Claudia Peitzsch
Journal:  Int J Radiat Biol       Date:  2014-08       Impact factor: 2.694

Review 2.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

3.  A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.

Authors:  Jonathan D Schoenfeld; Danielle N Margalit; Julie L Kasperzyk; Irene M Shui; Jennifer R Rider; Mara M Epstein; Allison Meisner; Stacey A Kenfield; Neil E Martin; Paul L Nguyen; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

Review 4.  Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization.

Authors:  C Alberti
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014-08       Impact factor: 3.507

5.  Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.

Authors:  Sebastian Kuger; Emre Cörek; Bülent Polat; Ulrike Kämmerer; Michael Flentje; Cholpon S Djuzenova
Journal:  Breast Cancer (Auckl)       Date:  2014-03-16

Review 6.  Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.

Authors:  Jingsong Zhang
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.